Background:
Warfarin has become the first choice for anticoagulation in
patients who need lifelong anticoagulation due to its clinical efficacy and low
price. However, the anticoagulant effect of warfarin is affected by many drugs,
foods, etc. accompanied by a high risk of bleeding and embolism. The Vitamin K
epoxide reductase complex 1 (
VKORC1
) and Cytochrome P450 2C9
(
CYP2C9
) genotypic variation can influence the therapeutic dose of
warfarin. However, it is not clear whether there is a correlation between
warfarin dose and liver function, kidney function and metabolic markers such as
uric acid (UA) in patients with different genotypes. We performed a single-center
retrospective cohort study to evaluate the factors affecting warfarin dose and to
establish a dose conversion model for warfarin patients undergoing heart valve
replacement.
Methods:
We studied 343 patients with a mechanical heart
valve replacement, compared the doses of warfarin in patients with different
warfarin-related genotypes (
CYP2C9
and
VKORC1
), and analyzed
the correlation between liver function, kidney function, UA and other metabolic
markers and warfarin dose in patients with different genotypes following heart
valve replacement.
Results:
Genotype analysis showed that 72.01% of
patients had
CYP2C9
*1/*1 and
VKORC1
mutant AA genotypes.
Univariate regression analysis revealed that the warfarin maintenance dose was
significantly correlated with gender, age, body surface area (BSA), UA and
genotype. There was no correlation with liver or kidney function. Multiple linear
regression analysis showed that BSA, genotype and UA were the independent factors
influencing warfarin dose.
Conclusions:
There is a significant
correlation between UA content and warfarin dose in patients with heart valve
replacement genotypes CYP2C9*1/*1/VKORC1(GA+GG), CYP2C9*1/*1/VKORC1AA and
CYP2C9*1/*1/VKORC1AA.